This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sucker, C. Articles by Zotz, R. B. Search for Related Content PubMed PubMed Citation Articles by Sucker, C. Articles by Zotz, R. B. Social Bookmarking                         What's this?

Determination of von Willebrand Factor Activity: Evaluation of the HaemosIL^TM Assay in Comparison With Established Procedures

Beate Senft

Rüdiger E. Scharf, MD, PhD

Rainer B. Zotz, MD

Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Duesseldorf, Germany

Determination of von Willebrand factor activity is required for diagnosis and classification of von Willebrand disease. In addition, von Willebrand factor activity can be of prognostic relevance in several clinical entities including thromboembolic and cardiovascular disorders in which elevated activity correlates with a poor prognosis. The HaemosIL^TM assay (Instrumentation Laboratory GmbH, Munich, Germany) provides a new fully automated procedure for determination of von Willebrand factor activity. This assay measures binding of the von Willebrand factor to GP Ib of the platelet glycoprotein complex Ib-V-IX. In our study, we analyzed 300 samples including those of patients with hereditary von Willebrand disease. The results obtained with the HaemosIL^TM assay were compared to von Willebrand factor activities determined by established procedures. Activities determined with HaemosIL^TM correlated with those activities determined as ristocetin cofactor (r = 0.88, p < 0.0001), collagen-binding (r = 0.93, p < 0.0001), and GP Ib-binding (r = 0.91, p < 0.0001). The comparability of results obtained by HaemosIL^TM and the GP Ib-binding ELISA were excellent ([HaemosIL^TM] = 0.96 activity [GP Ib-binding ELISA] + 10.7), whereas activities determined by ristocetin cofactor or collagen-binding revealed more variance. Like the other assays, the HaemosIL^TM failed to indicate a loss of high-molecular-weight von Willebrand factor multimers. The HaemosIL^TM assay can replace the GP Ib-binding ELISA for the determination of von Willebrand factor activity. Advantages of this assay include accuracy of results, full automation, and, thus, broad availability. Since the assay does not predict the absence of high-molecular-weight multimers, multimeric analysis remains the procedure of choice for the differentiation of functional defects.

Key Words: HaemosIL^TM • von Willebrand factor activity • GP Ib binding

Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 3, 305-310 (2006)
DOI: 10.1177/1076029606291428


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Pinol, M. Sales, M. Costa, A. Tosetto, M. T. Canciani, and A. B. Federici Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease Haematologica, May 1, 2007; 92(5): 712 - 713. [Abstract] [Full Text] [PDF]